US68236R1032 - Common Stock
ONCORUS INC
NASDAQ:ONCR (6/20/2023, 7:14:14 PM)
0.1206
-0.01 (-8.5%)
Oncorus, Inc. engages in the research and development of a viral immunotherapy platform. The company is headquartered in Andover, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2020-10-02. The Company’s two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The firm intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The firm is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The firm designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.
ONCORUS INC
4 Corporate Drive
Andover MASSACHUSETTS 02139
P: 18573206400.0
CEO: Theodore (Ted) Ashburn
Employees: 64
Website: https://mpmcapital.com/
It's time for another dive into the biggest pre-market stock movers as investors get ready to trade shares on Wednesday morning!
Cyxtera Technologies (CYXT) stock is falling Monday as the company continues with its bankruptcy filing and heavy trading pulls shares down.
Oncorus (ONCR) stock is taking a beating on Monday after revealing plans for a vote during an upcoming special shareholder meeting.
Here you can normally see the latest stock twits on ONCR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: